{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:01:03Z","timestamp":1775898063121,"version":"3.50.1"},"reference-count":56,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:p>Pimecrolimus is a calcineurin inhibitor developed for the topical treatment of atopic dermatitis. During the clinical development of 1% pimecrolimus cream, 1133 patients 3 to 23 months of age with mild to severe atopic dermatitis were treated for up to 2 years. The objective of this review is to discuss the safety and tolerability of 1% pimecrolimus cream among infants, on the basis of the combined results from all studies (4 pharmacokinetic studies and 6 clinical trials) conducted among these patients. Pimecrolimus blood concentrations measured for 35 patients were consistently low (\u22641 ng\/mL in &amp;gt;80% of samples), irrespective of the disease severity and extent, and remained low during intermittent treatment for up to 1 year. The level of systemic exposure to pimecrolimus among infants was comparable to that observed for older pediatric patients enrolled in the same studies and treated in the same way with 1% pimecrolimus cream, which indicated that young pediatric patients are not at higher risk of significant percutaneous absorption of topically applied pimecrolimus, despite their large skin surface area\/body mass ratio. The 6 clinical trials included a total of 1098 infants, who were treated for periods ranging from 4 weeks to 2 years. Most of these patients (60%) had moderate to severe disease at baseline. The most frequently reported adverse events were common childhood disorders such as nasopharyngitis, pyrexia, upper respiratory tract infections, ear infections, and bronchitis. During the double-blind (DB) studies or DB phases of studies, the incidence rates for the most frequently reported adverse events were similar for patients who received 1% pimecrolimus cream and patients who received the vehicle, except for the incidence of teething, which was higher among the pimecrolimus-treated infants (relative risk: 2.02; 95% confidence interval: 1.32\u20133.27). Treatment with 1% pimecrolimus cream was not associated with an increase in the overall incidence of nonskin infections, compared with the vehicle (relative risk: 1.015; 95% confidence interval: 0.88\u20131.18). The incidence density (ID) rates for total bacterial, fungal, parasitic, and viral skin infections during the DB studies or DB phases of studies were comparable for patients treated with 1% pimecrolimus cream and patients who received the vehicle. The ID rate of herpes simplex virus infections was 0.8 cases per 1000 patient-months of follow-up monitoring among patients treated with 1% pimecrolimus cream and 1.7 cases per 1000 patient-months of follow-up monitoring among patients who received the vehicle. Considering all 1098 infants treated with 1% pimecrolimus cream in DB trials and open-label studies, the ID rate of clinically diagnosed eczema herpeticum was 1.3 cases per 1000 patient-months of follow-up monitoring. Burning and erythema were the most frequently reported application site reactions, with ID rates of 2.0 and 1.2 cases per 1000 patient-months of follow-up monitoring, respectively. No sign of immunosuppression was found among infants treated intermittently with 1% pimecrolimus cream for up to 2 years; they demonstrated normal immune responses to vaccinations and did not show increases in the incidence of systemic infections or skin infections over time.<\/jats:p>","DOI":"10.1542\/peds.2005-1188","type":"journal-article","created":{"date-parts":[[2005,12,17]],"date-time":"2005-12-17T01:25:08Z","timestamp":1134782708000},"page":"e118-e128","source":"Crossref","is-referenced-by-count":99,"title":["Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years"],"prefix":"10.1542","volume":"117","author":[{"given":"Carle","family":"Paul","sequence":"first","affiliation":[{"name":"Clinical Research and Development, Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cork","sequence":"additional","affiliation":[{"name":"University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana B.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research, Waterloo, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Barbier","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"de Prost","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Necker-Enfants Malades Ho\u0302pital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2006,1,1]]},"reference":[{"key":"2021120819440747200_R1","doi-asserted-by":"crossref","unstructured":"Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol.\u20082003;112(suppl):S118\u2013S127","DOI":"10.1016\/j.jaci.2003.09.033"},{"key":"2021120819440747200_R2","doi-asserted-by":"crossref","unstructured":"Williams HC. Is the prevalence of atopic dermatitis increasing?Clin Exp Dermatol.\u20081992;17:385\u2013391","DOI":"10.1111\/j.1365-2230.1992.tb00244.x"},{"key":"2021120819440747200_R3","unstructured":"Schultz LF. The epidemiology of atopic dermatitis. Monogr Allergy.\u20081993;31:9\u201328"},{"key":"2021120819440747200_R4","doi-asserted-by":"crossref","unstructured":"Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol.\u20081994;30:35\u201339","DOI":"10.1016\/S0190-9622(94)70004-4"},{"key":"2021120819440747200_R5","doi-asserted-by":"crossref","unstructured":"Wadonda-Kabondo N, Sterne JA, Golding J, et al. A prospective study of the prevalence and incidence of atopic dermatitis in children aged 0\u201342 months. Br J Dermatol.\u20082003;149:1023\u20131028","DOI":"10.1111\/j.1365-2133.2003.05605.x"},{"key":"2021120819440747200_R6","doi-asserted-by":"crossref","unstructured":"Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants' Dermatitis Quality of Life Index. Br J Dermatol.\u20082001;144:104\u2013110","DOI":"10.1046\/j.1365-2133.2001.03960.x"},{"key":"2021120819440747200_R7","doi-asserted-by":"crossref","unstructured":"Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child.\u20081997;76:159\u2013162","DOI":"10.1136\/adc.76.2.159"},{"key":"2021120819440747200_R8","doi-asserted-by":"crossref","unstructured":"Queille C, Pommared R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis in childhood. Pediatr Dermatol.\u20081984;1:246\u2013253","DOI":"10.1111\/j.1525-1470.1984.tb01124.x"},{"key":"2021120819440747200_R9","unstructured":"Morley N. Minimising the use of topical steroids in children. Practitioner.\u20081988;232:949\u2013951"},{"key":"2021120819440747200_R10","unstructured":"Hepburn D, Yohn JJ, Weston WI. Topical steroid treatment in infants, children, and adolescents. Adv Dermatol.\u20081994;9:225\u2013254"},{"key":"2021120819440747200_R11","doi-asserted-by":"crossref","unstructured":"Oranje AP, Wolkerstorfer A. Advances in the treatment of atopic dermatitis with special regard to children. Curr Probl Dermatol.\u20081999;28:56\u201363","DOI":"10.1159\/000060600"},{"key":"2021120819440747200_R12","doi-asserted-by":"crossref","unstructured":"Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila).\u20082000;39:1\u201314","DOI":"10.1177\/000992280003900101"},{"key":"2021120819440747200_R13","doi-asserted-by":"crossref","unstructured":"Turpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol.\u20081988;118:517\u2013522","DOI":"10.1111\/j.1365-2133.1988.tb02461.x"},{"key":"2021120819440747200_R14","unstructured":"Saurat JH. Systemic side-effects of topical preparations in children. Sem Hop.\u20081982;58:1643\u20131649"},{"key":"2021120819440747200_R15","doi-asserted-by":"crossref","unstructured":"Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol.\u20081986;115:475\u2013484","DOI":"10.1111\/j.1365-2133.1986.tb06242.x"},{"key":"2021120819440747200_R16","doi-asserted-by":"crossref","unstructured":"Fisher G. Compliance problems in pediatric atopic eczema. Aust J Dermatol.\u20081996;37(suppl 1):10\u201313","DOI":"10.1111\/j.1440-0960.1996.tb01070.x"},{"key":"2021120819440747200_R17","doi-asserted-by":"crossref","unstructured":"Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol.\u20082000;142:931\u2013936","DOI":"10.1046\/j.1365-2133.2000.03473.x"},{"key":"2021120819440747200_R18","doi-asserted-by":"crossref","unstructured":"Fukaya M. Why do patients with atopic dermatitis refuse to apply topical corticosteroids?Dermatology.\u20082000;201:242\u2013245","DOI":"10.1159\/000018495"},{"key":"2021120819440747200_R19","doi-asserted-by":"crossref","unstructured":"Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in BL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res.\u20081998;290:501\u2013507","DOI":"10.1007\/s004030050343"},{"key":"2021120819440747200_R20","doi-asserted-by":"crossref","unstructured":"Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol.\u20081999;141:264\u2013273","DOI":"10.1046\/j.1365-2133.1999.02974.x"},{"key":"2021120819440747200_R21","doi-asserted-by":"crossref","unstructured":"Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg.\u20082001;20:233\u2013241","DOI":"10.1053\/sder.2001.29066"},{"key":"2021120819440747200_R22","unstructured":"Kalthoff F, Meingassner JG, Chung J, Kowalsky E, Stuetz A. Pimecrolimus is more cell-selective than corticosteroids: in vivo and in vitro data [abstract]. J Eur Acad Dermatol Venereol.\u20082002;16(suppl 1):257\u2013258"},{"key":"2021120819440747200_R23","doi-asserted-by":"crossref","unstructured":"Meingassner JG, Kowalsky E, Schwendinger H, Elbe-Buerger A, Stuetz A. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol.\u20082003;149:853\u2013857","DOI":"10.1046\/j.1365-2133.2003.05559.x"},{"key":"2021120819440747200_R24","doi-asserted-by":"crossref","unstructured":"Kalthoff FS, Chung J, Musser P, Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol.\u20082003;133:350\u2013359","DOI":"10.1046\/j.1365-2249.2003.02225.x"},{"key":"2021120819440747200_R25","doi-asserted-by":"crossref","unstructured":"Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Buerger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol.\u20082004;122:673\u2013684","DOI":"10.1111\/j.0022-202X.2004.22324.x"},{"key":"2021120819440747200_R26","doi-asserted-by":"crossref","unstructured":"Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stuetz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol.\u20081997;137:568\u2013576","DOI":"10.1111\/j.1365-2133.1997.tb03788.x"},{"key":"2021120819440747200_R27","doi-asserted-by":"crossref","unstructured":"Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm.\u20082004;269:29\u201335","DOI":"10.1016\/j.ijpharm.2003.07.013"},{"key":"2021120819440747200_R28","doi-asserted-by":"crossref","unstructured":"Queille-Roussel C, Paul C, Duteil C, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double blind controlled study. Br J Dermatol.\u20082001;144:507\u2013513","DOI":"10.1046\/j.1365-2133.2001.04076.x"},{"key":"2021120819440747200_R29","doi-asserted-by":"crossref","unstructured":"Hebert A, Warken KA, Cherill R. Pimecrolimus cream 1%: a new development in non-steroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg.\u20082001;20:260\u2013267","DOI":"10.1053\/sder.2001.29062"},{"key":"2021120819440747200_R30","doi-asserted-by":"crossref","unstructured":"Graham-Brown RAC, Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract.\u20082003;57:319\u2013327","DOI":"10.1111\/j.1742-1241.2003.tb10492.x"},{"key":"2021120819440747200_R31","doi-asserted-by":"crossref","unstructured":"Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol.\u20082003;17:493\u2013503","DOI":"10.1046\/j.1468-3083.2003.00692.x"},{"key":"2021120819440747200_R32","doi-asserted-by":"crossref","unstructured":"Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin diseases. Expert Opin Pharmacother.\u20082004;5:643\u2013655","DOI":"10.1517\/14656566.5.3.643"},{"key":"2021120819440747200_R33","unstructured":"Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis.\u20082000;42:349\u2013350"},{"key":"2021120819440747200_R34","doi-asserted-by":"crossref","unstructured":"Thac\u0327i D, Steinmeyer K, Ebelin ME, et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective: an open study. Dermatology.\u20082003;207:37\u201342","DOI":"10.1159\/000070939"},{"key":"2021120819440747200_R35","doi-asserted-by":"crossref","unstructured":"Kapp A, Papp K, Bingham A, et al. Flare Reduction in Eczema with Elidel (infants) multicentre investigator study group: long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol.\u20082002;110:277\u2013284","DOI":"10.1067\/mai.2002.126500"},{"key":"2021120819440747200_R36","doi-asserted-by":"crossref","unstructured":"Whalley D, Huels J, McKenna SP, van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics.\u20082002;110:1133\u20131136","DOI":"10.1542\/peds.110.6.1133"},{"key":"2021120819440747200_R37","doi-asserted-by":"crossref","unstructured":"Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr.\u20082003;142:155\u2013162","DOI":"10.1067\/mpd.2003.65"},{"key":"2021120819440747200_R38","doi-asserted-by":"crossref","unstructured":"Kaufmann R, Fo\u0308lster-Holst R, Ho\u0308ger P, et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol.\u20082004;114:1183\u20131188","DOI":"10.1016\/j.jaci.2004.08.015"},{"key":"2021120819440747200_R39","doi-asserted-by":"crossref","unstructured":"Papp KA, Werfel T, Fo\u0308lster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol.\u20082005;52:240\u2013246","DOI":"10.1016\/j.jaad.2004.09.016"},{"key":"2021120819440747200_R40","doi-asserted-by":"crossref","unstructured":"Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol.\u20082005;52:247\u2013253","DOI":"10.1016\/j.jaad.2004.08.046"},{"key":"2021120819440747200_R41","unstructured":"Food and Drug Administration. Novartis Elidel (pimecrolimus) cream 1% briefing document, 02-11-2005. Available at: www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/2005-4089b2_03_04_Elidel_20Novartis%20Briefing%20Bookredacted.pdf. Accessed May 12, 2005"},{"key":"2021120819440747200_R42","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Griffiths CEM, Ho VC, et al. Efficacy and tolerability of oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomised, dose-finding trial. Br J Dermatol.\u20082005;152:1219\u20131227","DOI":"10.1111\/j.1365-2133.2005.06661.x"},{"key":"2021120819440747200_R43","doi-asserted-by":"crossref","unstructured":"Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol.\u20082001;144:781\u2013787","DOI":"10.1046\/j.1365-2133.2001.04133.x"},{"key":"2021120819440747200_R44","doi-asserted-by":"crossref","unstructured":"Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child.\u20082003;88:969\u2013973","DOI":"10.1136\/adc.88.11.969"},{"key":"2021120819440747200_R45","unstructured":"Lakhanpaul M, Davies T, Allen B, Stephenson T, Scott G, Ebelin ME. Pimecrolimus (SDZ ASM 981) cream 1%: minimal systemic absorption in infants with atopic dermatitis during long-term treatment [abstract]. Ann Dermatol Venereol.\u20082002;129(suppl 1):415"},{"key":"2021120819440747200_R46","doi-asserted-by":"crossref","unstructured":"Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol.\u20082002;119:876\u2013887","DOI":"10.1046\/j.1523-1747.2002.00694.x"},{"key":"2021120819440747200_R47","doi-asserted-by":"crossref","unstructured":"David TJ, Longson M. Herpes simplex infections in atopic eczema. Arch Dis Child.\u20081985;60:338\u2013343","DOI":"10.1136\/adc.60.4.338"},{"key":"2021120819440747200_R48","unstructured":"Bonifazi E, Garofalo L, Pisani V, Meneghini CL. Role of some infectious agents in atopic dermatitis. Acta Derm Venereol Suppl (Stockh).\u20081985;114:98\u2013100"},{"key":"2021120819440747200_R49","doi-asserted-by":"crossref","unstructured":"Giannetti A. Viral skin diseases in atopic dermatitis. In: Happle R, Grosshans E, eds. Pediatric Dermatology. Berlin, Germany: Springer-Verlag; 1987:110\u2013113","DOI":"10.1007\/978-3-642-71524-2_14"},{"key":"2021120819440747200_R50","doi-asserted-by":"crossref","unstructured":"David TJ, Cambridge GC. Bacterial infections in atopic eczema. Arch Dis Child.\u20081986;61:20\u201323","DOI":"10.1136\/adc.61.1.20"},{"key":"2021120819440747200_R51","doi-asserted-by":"crossref","unstructured":"Gold E, Fevrier A, Hatch MH, et al. Immune status of children one to four years of age as determined by history and antibody measurement. N Engl J Med.\u20081973;289:231\u2013235","DOI":"10.1056\/NEJM197308022890502"},{"key":"2021120819440747200_R52","doi-asserted-by":"crossref","unstructured":"Edmunds WJ, Pebody RG, Aggerback H, et al. The sero-epidemiology of diphtheria in Western Europe: ESEN Project: European Sero-Epidemiology Network. Epidemiol Infect.\u20082000;125:113\u2013125","DOI":"10.1017\/S0950268899004161"},{"key":"2021120819440747200_R53","doi-asserted-by":"crossref","unstructured":"De Melker H, Pebody RG, Edmunds WG, et al. The seroepidemiology of measles in Western Europe. Epidemiol Infect.\u20082001;126:249\u2013259","DOI":"10.1017\/S0950268801005234"},{"key":"2021120819440747200_R54","doi-asserted-by":"crossref","unstructured":"Pebody RG, Edmunds WJ, Conyn-van Spaendonck M, et al. The seroepidemiology of rubella in Western Europe. Epidemiol Infect.\u20082000;125:347\u2013357","DOI":"10.1017\/S0950268899004574"},{"key":"2021120819440747200_R55","doi-asserted-by":"crossref","unstructured":"Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer.\u20082001;85:683\u2013686","DOI":"10.1054\/bjoc.2001.1931"},{"key":"2021120819440747200_R56","doi-asserted-by":"crossref","unstructured":"Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst.\u20082004;96:709\u2013711","DOI":"10.1093\/jnci\/djh118"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/1\/e118\/1010207\/zpe0010600e118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/1\/e118\/1010207\/zpe0010600e118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T22:53:29Z","timestamp":1683327209000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/1\/e118\/67954\/Safety-and-Tolerability-of-1-Pimecrolimus-Cream"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2006,1,1]]},"published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-1188","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}